Top

Published in:

01-09-2016 | Clinical Study

Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes

Authors: James E. Bates, Gyujae Choi, Michael T. Milano

Published in: Journal of Neuro-Oncology | Issue 2/2016

Abstract

Myxopapillary ependymoma (MPE) is an exceedingly rare tumor histology. While surgery is clearly the treatment of choice, controversy exists regarding the role of adjuvant radiotherapy (RT). Using the Surveillence, epidemiology, and end results (SEER) database, we aimed to determine the epidemiology, prognostic factors, and treatment-related outcomes for MPE. A total of 773 cases were found in the SEER database. The incidence in the American population was found to be 1.00 per million person-years. On multivariate analysis, receipt of surgery (HR = 0.14, CI = 0.06–0.35, p < 0.001), receipt of RT (HR = 4.06, CI = 1.87–8.81, p < 0.001), age less than 30 (HR = 0.24, CI = 0.08–0.72, p = 0.01), and Caucasian race (HR = 0.37, CI = 0.13–0.996, p = 0.049) were statistically significant prognostic factors. The mean tumor size among those receiving RT (4.6 cm) was significantly larger than among those not receiving RT (3.2 cm, p = 0.0002). Those who lived in metropolitan areas were more likely to receive RT than those who did not. Given multiple previous studies show that RT improves PFS and the discrepancy in tumor size, selection bias is likely a significant contributor to the apparent negative impact of RT on OS. Regardless, surgery remains the most crucial aspect in the care of patients with MPE.

Reni M, Gatta G, Mazza E, Vecht C (2007) Ependymoma. Crit Rev Oncol Hematol 63:81–89. doi:10.1016/j.critrevonc.2007.03.004 CrossRefPubMed

Tsai CJ, Wang Y, Allen PK, Mahajan A, McCutcheon IE, Rao G, Rhines LD, Tatsui CE, Armstrong TS, Maor MH, Chang EL, Brown PD, Li J (2014) Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson cancer center experience. Neurosurgery 75:205–214. doi:10.1227/neu.0000000000000408 (discussion 213–204)CrossRefPubMed

Bates JE, Peterson CR 3rd, Yeaney GA, Walter KA, Lundquist T, Rosenzweig D, Milano MT (2014) Spinal drop metastasis in myxopapillary ependymoma: a case report and a review of treatment options. Rare Tumors 6:5404. doi:10.4081/rt.2014.5404 CrossRefPubMedPubMedCentral

Fegerl G, Marosi C (2012) Stabilization of metastatic myxopapillary ependymoma with sorafenib. Rare Tumors 4:e42. doi:10.4081/rt.2012.e42 CrossRefPubMedPubMedCentral

Khalatbari MR, Jalaeikhoo H, Hamidi M, Moharamzad Y (2013) Craniospinal dissemination of filum myxopapillary ependymoma following spinal trauma: case report and literature review. Childs Nerv Syst 29:149–152. doi:10.1007/s00381-012-1927-1 CrossRefPubMed

Bostrom A, von Lehe M, Hartmann W, Pietsch T, Feuss M, Bostrom JP, Schramm J, Simon M (2011) Surgery for spinal cord ependymomas: outcome and prognostic factors. Neurosurgery 68:302–308. doi:10.1227/NEU.0b013e3182004c1e (discussion 309)CrossRefPubMed

Feldman WB, Clark AJ, Safaee M, Ames CP, Parsa AT (2013) Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine 19:471–476. doi:10.3171/2013.6.spine12927 CrossRefPubMed

Lee SH, Chung CK, Kim CH, Yoon SH, Hyun SJ, Kim KJ, Kim ES, Eoh W, Kim HJ (2013) Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea spinal. Oncol Res Group Neuro Oncol 15:921–929. doi:10.1093/neuonc/not038 CrossRef

Lin Y, Smith ZA, Wong AP, Melkonian S, Harris DA, Lam S (2015) Predictors of survival in patients with spinal ependymoma. Neurol Res 37:650–655. doi:10.1179/1743132815y.0000000041 CrossRefPubMed

10.

Nakamura M, Ishii K, Watanabe K, Tsuji T, Matsumoto M, Toyama Y, Chiba K (2009) Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine (Phila Pa 1976) 34:E756–760 doi:10.1097/BRS.0b013e3181b34d16 CrossRefPubMed

11.

Schild SE, Nisi K, Scheithauer BW, Wong WW, Lyons MK, Schomberg PJ, Shaw EG (1998) The results of radiotherapy for ependymomas: the mayo clinic experience. Int J Radiat Oncol Biol Phys 42:953–958CrossRefPubMed

12.

Weber DC, Wang Y, Miller R, Villa S, Zaucha R, Pica A, Poortmans P, Anacak Y, Ozygit G, Baumert B, Haller G, Preusser M, Li J (2015) Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson cancer center and institutions from the rare cancer network. Neuro Oncol 17:588–595. doi:10.1093/neuonc/nou293 CrossRefPubMed

13.

Abdulaziz M, Mallory GW, Bydon M, De la Garza Ramos R, Ellis JA, Laack NN, Marsh WR, Krauss WE, Jallo G, Gokaslan ZL, Clarke MJ (2015) Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. Neurosurg Focus 39:E8 doi:10.3171/2015.5.focus15164 CrossRefPubMed

14.

Sonneland PR, Scheithauer BW, Onofrio BM (1985) Myxopapillary ependymoma. a clinicopathologic and immunocytochemical study of 77 cases. Cancer 56:883–893CrossRefPubMed

15.

Nagasawa DT, Smith ZA, Cremer N, Fong C, Lu DC, Yang I (2011) Complications associated with the treatment for spinal ependymomas. Neurosurg Focus 31:E13. doi:10.3171/2011.7.focus11158 CrossRefPubMed

16.

Agbahiwe HC, Wharam M, Batra S, Cohen K, Terezakis SA (2013) Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys 85:421–427. doi:10.1016/j.ijrobp.2012.05.001 CrossRefPubMed

17.

Akyurek S, Chang EL, Yu TK, Little D, Allen PK, McCutcheon I, Mahajan A, Maor MH, Woo SY (2006) Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson cancer center. J Neurooncol 80:177–183. doi:10.1007/s11060-006-9169-2 CrossRefPubMed

18.

Al-Halabi H, Montes JL, Atkinson J, Farmer JP, Freeman CR (2010) Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas. Pediatr Blood Cancer 55: 639–643 doi:10.1002/pbc.22614 CrossRefPubMed

19.

Pica A, Miller R, Villa S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert BG, Zaucha R, Haller G, Weber DC (2009) The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys 74:1114–1120. doi:10.1016/j.ijrobp.2008.09.034 CrossRefPubMed

20.

Chao ST, Kobayashi T, Benzel E, Reddy CA, Stevens GH, Prayson RA, Kalfas I, Schlenk R, Krishnaney A, Steinmetz MP, Bingaman W, Hahn J, Suh JH (2011) The role of adjuvant radiation therapy in the treatment of spinal myxopapillary ependymomas. J Neurosurg Spine 14:59–64. doi:10.3171/2010.9.spine09920 CrossRefPubMed

21.

Kukreja S, Ambekar S, Sin AH, Nanda A (2014) Cumulative survival analysis of patients with spinal myxopapillary ependymomas in the first 2 decades of life. J Neurosurg Pediatr 13:400–407. doi:10.3171/2014.1.peds13532 CrossRefPubMed

22.

Surveillance Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) (released April 2015, based on the November 2014 submission). Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973–2012 varying). In: National Cancer Institute D, Surveillance Research Program, Surveillance Systems Branch (ed).

23.

Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL (2015) Epidemiology of meningiomas post-public law 107–206: the benign brain tumor cancer registries amendment act. Cancer 121:2400–2410. doi:10.1002/cncr.29379 CrossRefPubMed

24.

Parker T (2015) United States Department of agriculture economic research service rural-urban continuum codes documentation. http://www.ers.usda.gov/data-products/rural-urban-continuum-codes/documentation.aspx. Accessed November 2 2015

25.

Kukreja S, Ambekar S, Sharma M, Sin AH, Nanda A (2015) Outcome predictors in the management of spinal myxopapillary ependymoma: an integrative survival analysis. World Neurosurg 83:852–859. doi:10.1016/j.wneu.2014.08.006 CrossRefPubMed

26.

Oh MC, Tarapore PE, Kim JM, Sun MZ, Safaee M, Kaur G, Aranda DM, Parsa AT (2013) Spinal ependymomas: benefits of extent of resection for different histological grades. J Clin Neurosci 20:1390–1397. doi:10.1016/j.jocn.2012.12.010 CrossRefPubMedPubMedCentral

27.

Cimino PJ, Agarwal A, Dehner LP (2014) Myxopapillary ependymoma in children: a study of 11 cases and a comparison with the adult experience. Pediatr Blood Cancer 61:1969–1971 doi:10.1002/pbc.25125 CrossRefPubMed

28.

Fassett DR, Pingree J, Kestle JR (2005) The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg 102:59–64. doi:10.3171/ped.2005.102.1.0059 CrossRefPubMed

29.

Milano MT, Johnson MD, Sul J, Mohile NA, Korones DN, Okunieff P, Walter KA (2010) Primary spinal cord glioma: a surveillance, epidemiology, and end results database study. J Neurooncol 98:83–92. doi:10.1007/s11060-009-0054-7 CrossRefPubMed

30.

Graf M, Blaeker H, Otto HF (1999) Extraneural metastasizing ependymoma of the spinal cord. Pathol Oncol Res 5:56–60CrossRefPubMed

31.

Baldwin LM, Patel S, Andrilla CH, Rosenblatt RA, Doescher MP (2012) Receipt of recommended radiation therapy among rural and urban cancer patients. Cancer 118:5100–5109. doi:10.1002/cncr.27488 CrossRefPubMed

32.

Martinez SR, Shah DR, Tseng WH, Canter RJ, Bold RJ (2012) Rural-urban disparities in use of post-lumpectomy radiation. Med Oncol 29:3250–3257. doi:10.1007/s12032-012-0266-0 CrossRefPubMed

33.

Martinez SR, Tseng WH, Shah DR, Canter RJ, Bold RJ (2012) Urban and non-urban disparities in the use of post-mastectomy radiation for breast cancer. Med Oncol 29:1523–1528. doi:10.1007/s12032-011-0077-8 CrossRefPubMed

34.

Schootman M, Aft R (2001) Rural-urban differences in radiation therapy for ductal carcinoma in-situ of the breast. Breast Cancer Res Treat 68:117–125CrossRefPubMed

35.

Amsbaugh MJ, Grosshans DR, McAleer MF, Zhu R, Wages C, Crawford CN, Palmer M, De Gracia B, Woo S, Mahajan A (2012) Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes. Int J Radiat Oncol Biol Phys 83:1419–1424. doi:10.1016/j.ijrobp.2011.10.034 CrossRefPubMed

36.

Indelicato DJ, Flampouri S, Rotondo RL, Bradley JA, Morris CG, Aldana PR, Sandler E, Mendenhall NP (2014) Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy. Acta Oncol 53:1298–1304. doi:10.3109/0284186x.2014.957414 CrossRefPubMed

37.

Mizumoto M, Oshiro Y, Takizawa D, Fukushima T, Fukushima H, Yamamoto T, Muroi A, Okumura T, Tsuboi K, Sakurai H (2015) Proton beam therapy for pediatric ependymoma. Pediatr Int 57:567–571. doi:10.1111/ped.12624 CrossRefPubMed

38.

Mack SC, Agnihotri S, Bertrand KC, Wang X, Shih DJ, Witt H, Hill N, Zayne K, Barszczyk M, Ramaswamy V, Remke M, Thompson Y, Ryzhova M, Massimi L, Grajkowska W, Lach B, Gupta N, Weiss WA, Guha A, Hawkins C, Croul S, Rutka JT, Pfister SM, Korshunov A, Pekmezci M, Tihan T, Philips JJ, Jabado N, Zadeh G, Taylor MD (2015) Spinal myxopapillary ependymomas demonstrate a warburg phenotype. Clin Cancer Res 21:3750–3758. doi:10.1158/1078-0432.ccr-14-2650 CrossRefPubMedPubMedCentral

39.

Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ (2012) Underascertainment of radiotherapy receipt in surveillance, epidemiology, and end results registry data. Cancer 118:333–341. doi:10.1002/cncr.26295 CrossRefPubMed

40.

Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL (2014) Comparison of SEER treatment data with medicare claims. Med Care. doi:10.1097/mlr.0000000000000073

Title: Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes
Authors: James E. Bates
Gyujae Choi
Michael T. Milano
Publication date: 01-09-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2167-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo

Stereotactic biopsy of brainstem lesions: 21 years experiences of a single center

MicroRNA-132 targets PEA-15 and suppresses the progression of astrocytoma in vitro

Clinical ramifications of “genomic staging” of low-grade gliomas

Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma

Cognitive outcomes among survivors of focal low-grade brainstem tumors diagnosed in childhood